Wed, July 27, 2011
Tue, July 26, 2011
Mon, July 25, 2011
Sat, July 23, 2011
Fri, July 22, 2011
Thu, July 21, 2011
Wed, July 20, 2011
[ Wed, Jul 20th 2011 ]: Market Wire
Pfizer To Acquire Icagen
[ Wed, Jul 20th 2011 ]: Market Wire
00 a.m. EDT
Tue, July 19, 2011
Mon, July 18, 2011
[ Mon, Jul 18th 2011 ]: Market Wire
Aetna to Acquire PayFlex
Fri, July 15, 2011
Thu, July 14, 2011
Wed, July 13, 2011
Tue, July 12, 2011
Mon, July 11, 2011
Sun, July 10, 2011
Sat, July 9, 2011
Fri, July 8, 2011
Thu, July 7, 2011
Wed, July 6, 2011
Tue, July 5, 2011
Mon, July 4, 2011
Sat, July 2, 2011
Fri, July 1, 2011
Thu, June 30, 2011

POZEN Announces July 28, 2011 Webcast of Second Quarter 2011 Results


  Copy link into your clipboard //health-fitness.news-articles.net/content/2011/ .. 2011-webcast-of-second-quarter-2011-results.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

CHAPEL HILL, N.C.--([ BUSINESS WIRE ])--POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release second quarter 2011 results on July 28, 2011, before the market opens.

The announcement will be followed by a live webcast at 11:00 a.m. (EDT) with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZENa™s website at [ www.pozen.com ] and will be archived and available for replay. The second quarter 2011 earnings release will be accessible in the News section of POZENa™s website.

About POZEN

POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years a" something almost no other small pharmaceutical company has done. Funded by these two milestone/royalty streams, POZEN is now creating a portfolio of cost-effective, evidence based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage. The lead candidate, PA32540, is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers and has entered Phase 3 clinical trials. POZEN is retaining commercial control of the pipeline assets and will develop a 21st century sales and marketing organization using a new sales force model and digital communications. The Company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN". For more detailed company information, including copies of this and other press releases, please visit: [ www.pozen.com ].


Publication Contributing Sources